Lilly
Investors Hangout: Collaboration to Enhance Alzheimer’s Research with Eli Lilly Strategic Partnership in Alzheimer’s Research
The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]
Read more »
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]
Read more »